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Abstract
Background: Tumor cell contamination of the apheresis in multiple myeloma is likely to affect disease-free and
overall survival after autografting.
Objective: To purge myeloma aphereses from tumor contaminants with a novel culture-based purging method.
Methods:  We cultured myeloma-positive CD34+ PB samples in conditions that retained multipotency of
hematopoietic stem cells, but were unfavourable to survival of plasma cells. Moreover, we exploited the
resistance of myeloma plasma cells to retroviral transduction by targeting the hematopoietic CD34+ cell
population with a retroviral vector carrying a selectable marker (the truncated form of the human receptor for
nerve growth factor, ΔNGFR). We performed therefore a further myeloma purging step by selecting the
transduced cells at the end of the culture.
Results: Overall recovery of CD34+ cells after culture was 128.5%; ΔNGFR transduction rate was 28.8% for
CD34+ cells and 0% for CD138-selected primary myeloma cells, respectively. Recovery of CD34+ cells after
ΔNGFR selection was 22.3%. By patient-specific Ig-gene rearrangements, we assessed a decrease of 0.7–1.4 logs
in tumor load after the CD34+ cell selection, and up to 2.3 logs after culture and ΔNGFR selection.
Conclusion: We conclude that ex-vivo culture and retroviral-mediated transduction of myeloma leukaphereses
provide an efficient tumor cell purging.
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Background
The standard therapy for multiple myeloma is high-dose
chemotherapy with autologous reinfusion of hematopoi-
etic stem cells [1-3]. Molecular evidences indicate that
residual cancer cells contaminate the transplant, and sev-
eral reports estimate a tumor burden of 104 – 109 plasma
cells per transplant [4,5]. Although their role in determin-
ing patients' overall survival is still unclear, a correlation
has been shown between a plasma cell contamination >2
× 105/lt and an early relapse [6,7]. In an effort to over-
come this problem, a purging approach of aphereses was
developed with a positive selection of CD34+ cells, but no
significant clinical advantage was achieved with this
method [8]. Recent studies show that 75% of aphereses
are still contaminated with plasma cells after the CD34+
selection [9]. Other purging approaches exploited a more
restricted phenotypic selection to eliminate tumor con-
taminants, such as CD34+/lin-/Thy1+ [10,11], or com-
bined selections (CD34+/CD19-) [12]. For both methods,
preliminary clinical results indicate good purging achieve-
ments, but high infection rates, and poor bone marrow
reconstitution results, due to the effects of progenitor- and
T-cells depletion [11]. Barbui et al. described a purging
approach based on negative selection of mobilized blood
stem cells [13], in which they achieve safe engraftment
results with purged cell grafts, but without advantages in
the overall survival of patients. A wide variability of purg-
ing results – ranging from 0 to 7 logs depletions – is
achieved by these phenotype-based purging methods.
Still no clinical trial so far established a defined threshold
of purging necessary to reduce the risk of relapse while
maintaining a safe clinical feasibility.
We investigated the efficiency of a culture-based purging
of myeloma aphereses.
Myeloma plasma cells exhibit a high mortality in culture
(50–95% in 9 days) [14]; we exploited this biological
behaviour to perform a culture-based purging of myeloma
CD34-selected leukaphereses. We designed a 4-day
cytokine-culture procedure, adequate for a safe mainte-
nance of the CD34+  cell multilineage phenotype, but
unfavourable to plasma cells. Moreover myeloma cells
display a very low retroviral-mediated transduction rate,
even after repeated infection cycles (1.5–5.4%) [14,15],
therefore we structured the protocol to allow the insertion
and the expression of retroviral genes in the CD34+ cells.
Through this approach, we directed the selectable marker
ΔNGFR to the CD34+ cell population, adding a further
purging possibility. ΔNGFR has already been utilized in T
cell populations to control GvHD in allogeneic bone mar-
row transplants [16,17]. To assess the effectiveness of
purging, we amplified patient-specific, clonal tumor
immunoglobulin heavy-chain (IgH) rearrangements
before and after CD34+ cell culture procedure and retrovi-
ral transduction.
We present here the results of culture and transduction of
primary cells from leukaphereses of 19 multiple myeloma
(MM) patients, undergoing high-dose chemotherapy and
peripheral blood cell autografting.
Methods
Cell processing
Mobilized peripheral blood (MPB) and bone marrow
(BM) cells were collected from MM patients enrolled in
high-dose chemotherapy programs, approved by IRB at
HSR, after informed consent. Mononuclear cells were
purified by density centrifugation using the lymphocyte
separation medium Lymphoprep (Nycomed Pharma,
Asker, Norway).
CD34+ cells were positively selected using the following
immunomagnetic separation devices: mini-, and midi-
MACS (CD34+ MultiSort Kit, Miltenyi Biotec, Bergisch
Gladbach, Germany), cliniMACS (Miltenyi Biotec),
ISOLEX300i (Baxter Healthcare, Irvine, CA, USA), accord-
ing to the manufacturer's instructions. CD138+ cells were
selected with mini-MACS device, using direct conjugated
anti CD138 microbeads (Miltenyi Biotec). Immunose-
lected cells were analyzed by flow-cytometry, to deter-
mine the purity of selections.
Retroviral supernatant production
BML-1 Moloney Murine Leukemia Virus (MoMLV) based
retrovirus, containing the ΔNGFR marker gene under the
control of LTR promoter [18] was collected from producer
cells, kindly provided by Roche Diagnostics GmbH. Pro-
ducer cells were expanded in 200 μl/cm2 Iscove's modified
Dulbecco's medium (IMDM, Bio Whittaker, Verviers, Bel-
gium) supplemented with 10% fetal bovine serum (FCS,
Euroclone, Wetherby, West Yorkshire, UK), 100 U/ml
penicillin-streptomycin, and 2 mM L-glutamine at 5 × 104
cells/cm2, at 37°C with 5% CO2. The medium was
replaced after 48 hours, 72 hours and 84 hours reducing
the volume to 66 μl/cm2 and the temperature to 33°C
[19]. Viral supernatant (SN) was collected with 12-hours
serial collections, 0.45 filtered and -80°C frozen before
use.
Culture, transduction and selection of transduced cells
CD34+ cells were cultured in X-Vivo 10 (Bio Whittaker)
serum free medium containing the cytokines throm-
bopoietin (PeproTech, Rocky Hill, NJ, USA), FLT3-Iigand
(PeproTech), stem cell factor (R&D Systems Minneapolis,
MN, USA) at 50 ng/ml (thereafter designated complete
medium) at 5–6 × 105cells/cm2 for 84 hours. Transduc-
tion of CD34+ cells were performed in complete medium,
at the same cell concentration. Cells were prestimulatedJournal of Translational Medicine 2007, 5:35 http://www.translational-medicine.com/content/5/1/35
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for 24 hours, and overnight transduced with the BML-1
retroviral vector on RetroNectin (TaKara Biomedicals,
Kyoto, Japan)-coated non-tissue culture-treated plates, or
T75 flasks, with 4:1 v/v SN/culture medium, supple-
mented with 5× concentrated cytokines. Fresh complete
medium was replaced after virus withdrawal and cells
were cultured for further 48 hours. At the end of the cul-
ture, cells were collected, washed, and incubated with
anti-NGFR biotinylated antibody at 2.5 × 106 cell/ml for
30 minutes at 4°C and then with 10 μl streptavidin (SA)-
conjugated microbeads (Miltenyi Biotec) for 15 minutes
at 4°C. ΔNGFR+ cells were then isolated by mini-MACS
immunoselection device. ΔNGFR positive and negative
fractions were analyzed by flow-cytometry for CD34,
CD45, CD138, and ΔNGFR antigens. Clonal transduction
of CD138+  cells was performed in U-bottom 96-well
plates with 4:1 SN/culture medium only in wells scored
positive for 1 cell at light microscope. Prestimulation was
performed with 40 μl of complete medium, and after 24
hours, 128 μl of virus, complemented with 32 μl of 5×
cytokines, were directly added to each well. To avoid dis-
turbance of the cells, transduction was stopped by substi-
tuting 150 μl of medium with fresh complete medium.
Doubling of single cells was scored daily by microscopy
and viability of cells using Trypan blue exclusion assessed
at the end of transduction.
Immunofluorescence staining and flow cytometric 
analyses
Cells were stained with conjugated monoclonal antibod-
ies (mAbs) in 100 μl PBS, 0,1% sodium-azide, 0,3% BSA
(PBS FACS) at 4°C for 25 minutes, after the staining cells
were washed and resuspended in PBS FACS. For bioti-
nylated mAbs a secondary staining with streptavidin-PE/
FITC was performed. The following mAbs were used:
CD34-PE (Becton Dickinson, San Josè, California, USA),
CD45-FITC/TC (Caltag, Burlingame, California, USA),
CD138-FITC (Valter Occhiena, Torino, Italy), CD38-TC
(Caltag), SA-FITC/PE/TC (Caltag), biotinylated-NGFR.
Isotype-identical mAbs IgG1-FITC/PE/TC and bioti-
nylated-IgG1 (Caltag) served as control. Samples were
acquired with FacsScan device (Becton Dickinson). Data
were analyzed using CellQuest software (Becton Dickin-
son).
In vitro clonogenic cell assays
Long-term marrow cultures (LTMC) were performed
according to a described procedure [20]. Briefly, 70000
CD34+/ΔNGFR+ cells were seeded on top of MS5 murine
stromal cells in Myelocult medium (StemCell Technolo-
gies, Vancouver, BC, CA), added with 10 ng/ml IL6 (Pepro
Tech) and half of the medium was weekly replaced. After
three weeks of culture, cells were resuspended in Methoc-
ult GF medium (StemCell Technologies) and plated in
duplicate in a (Colony Forming Units-Cells) CFU-C assay.
Colonies were scored two weeks later, individually picked
and DNA was extracted for PCR analysis. DNA extraction
was performed adding, for each colony, 25 μl of KCl lysis
buffer and protease K at 50 μg/ml. Colonies were incu-
bated overnight at 37°C and heat inactivated for 15' at
94°C. KCl lysis buffer consists of 1:1 v/v mix of solution
A (100 mM KCl, 10 mM Tris pH 8.3, 2.5 mM MgCl2) and
solution B (10 mM Tris pH 8.3, 2.5 mM MgCl2, 1%
Tween-20, 1% NP-40). DNA was then analyzed for the
presence of ΔNGFR transgene, and patient-specific mye-
loma markers.
PCR assays
To determine the presence of ΔNGFR transgene, DNA was
amplified with primers 5'-LΔ1: GGCCGTTGGATTA-
CACGGTC and 3'-MAGO: CCTACAGGTGGGGTCTTTCA.
PCR reactions were carried out in a final volume of 25 μl,
with 1 μM primers, 2.5 mM MgCl2, 0.25 mM dNTPs and
1.25 U Taq Gold (Perkin Elmer, Wellesley, MA, USA), at
following conditions: 7 minutes at 94°C, 50 seconds at
94°C, 50 seconds at 60°C and 50 seconds at 72°C for 40
cycles, 5 minutes at 72°C. As a control for the presence of
DNA, HLA genes were amplified (primer 5':GTGCT-
GCAGGTGTAAACTTGTACCAG and primer 3':CACG-
GATCCGGTAGCAGCGGTAGAGTTG). PCR conditions
were the same as above, except for annealing temperature
that was 56°C.
To detect tumor cells, the clonal variable region (VDJ)
rearrangements of the IgH genes of each patient were
amplified using 5' consensus primers derived from the
conserved sequences of the variable region and 3' consen-
sus primer derived from the joining region as previously
described [21]. PCR products were sequenced and
sequences from CDR2 and CDR3 regions were used to
design patient-specific tumor primers. Oligonucleotides
were subsequently tested for specificity using polyclonal
DNA from normal individuals as negative controls. For
each patient, CD34+ cells before and after culture, and
after ΔNGFR immunoselection were amplified to detect
residual myeloma cells. Cells were directly resuspended at
1 × 105/50  μl in KCl lysis solution for genomic DNA
extraction (as described above) and PCR amplifications
were performed using 5, or 10 μl of DNA. A first round
PCR was performed using patient specific VH family prim-
ers and a second round was performed amplifying 1 μl of
the first PCR product with patient-specific primers. The
sensitivity was 10-4-10-5 [21].
Limiting dilution assays were performed serially diluting
DNA with water, in 0.5 log increments and each dilution
was subsequently amplified with patient-specific primers.
At least five PCR reactions were performed for each dilu-
tion level from the level in which reactions were positive
up to the level in which all reactions were negative forJournal of Translational Medicine 2007, 5:35 http://www.translational-medicine.com/content/5/1/35
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clonal markers. Polyclonal DNA was always included as
negative control. This technique has been previously vali-
dated by diluting a known number of tumor cells in nor-
mal marrow or peripheral blood cells. An indirect
quantification of the tumor load in the positive samples
of the dilution was performed according to the statistical
methods of likelihood maximization and χ2 minimiza-
tion (MC), derived from the single-hit Poisson model, as
described by Taswell [22]. Combined frequency estimates
were obtained by analyzing with MC estimator the pooled
frequency determinations. Comparison of frequencies
between groups was performed through evaluation of
confidence interval (CI) and probability value, and CI for
the ratio of 2 frequencies. All calculations were performed
using MATLAB (version 5, The Math Works Inc.).
Results
Culture of myeloma aphereses, transduction and selection 
procedures
Nineteen MPB leukaphereses products were CD34-
selected by miniMACS (n = 15), midiMACS (n = 1), clin-
iMACS (n = 1) or ISOLEX immunoselection system (n =
2). Mean purity of CD34+ cells was 80.6 ± 19% (Table 1).
CD34+  cells were cultured for 84 hours, in complete
medium. We previously described that this protocol
allows a safe expansion of multipotent progenitors, with-
out impairing their reconstitution capacity in severe com-
bined immunodeficiency-humanized (SCID-hu) mice
[18]. A portion of the CD34+ cells was exposed to a retro-
viral transduction: after 24 hours of culture with complete
medium, cells were overnight transduced with a MoMLV-
derived retroviral vector, carrying the ΔNGFR gene [17].
After transduction, viral supernatant was replaced with
fresh complete medium, and cells were allowed to express
the transgene for further 48 hours (total culture time 84
hours, as in the non-retroviral exposed cytokine-culture).
Transduced cells were immunoselected by ΔNGFR expres-
sion with MACS immunoselection system (Figure 1A), as
previously described [23]. Mean CD34+ cells transduction
rate was 28.9 ± 12%, and purity of ΔNGFR immunose-
lected CD34+ cells was 92.5 ± 5%.
At the end of the procedure, 67.7 ± 13% of ΔNGFR
selected cells still retained the CD34 phenotype, indicat-
ing a recovery of 22.3 ± 15% of the initial CD34+ cell
number (Table 1).
We did not observe differences in results when we per-
formed the procedure with high numbers of CD34+ cells
(Table 1: exp. MM12, and MM14).
Mean fold-expansion of cytokine-cultured cells was 1.4,
and CD34+ cells after culture were 128.5% of the initial
number. CD34+ antigen expression was 91.8 ± 4% after
cytokine culture, and 67,7 ± 13% after transduction and
selection of ΔLNGFR+ cells. Recovery of total cells and
CD34+ cells in a representative experiment is shown in
Figure 1B.
Molecular purging
To assess the results of myeloma-cell purging, we devel-
oped patient-specific primers for tumor-specific mono-
clonal immunoglobulin gene rearrangements in 9
patients (MM#3,6,10/14,12,13,15,16,18 and 19). We
amplified by PCR complementary determining regions I
and III of the heavy chain VDJ immunoglobulin frag-
ments, and we monitored monoclonal residual rearrange-
ments in the apheresis product, after CD34+ selection,
after culture and after transduction. Mononuclear cells,
CD34+ fresh cells, cytokines-cultured cells, and ΔLNGFR-
positive and -negative selected fractions were analyzed in
10 experiments, and DNA was amplified for myeloma
specific clonal rearrangements.
Undiluted DNA was first amplified in 5 PCR reactions for
each patient. Only in samples where sufficient material
was available (n = 6), serial 0.5 log dilutions of DNA were
performed before amplification, to allow a quantification
of the purging. Results of the amplifications were inter-
preted with a Poisson estimate [22]. Since no quantitative
real-time PCR has been performed, the results should be
taken in relative terms (logdecreaseoftheinitialcell fre-
quency). When we amplified DNA from mobilized
aphereses, 83.3% of samples showed detectable myeloma
contaminants, and 77.8% of the samples still retained
myeloma cells after CD34+ antigen selection (Table 2, gray
shaded cells). The amount of tumor decrease after this
first purging-step ranged from <0.67 to 1.36 logs. After ex-
vivo cytokine culture, 57.1% (4 out of 7) tumor-positive
CD34+  samples lost myeloma specific rearrangements
(MM6,14,18,19), with an estimation of 0 to >2.35 logs
purging, with respect to the initial tumor load. We then
measured how cell exposure to retroviral vector, and selec-
tion of transgene-expressing cells contributed to the purg-
ing. All the samples purged after cytokines-culture were
also PCR negative for myeloma specific rearrangements
after transduction and selection of the ΔNGFR+ cell frac-
tion. Among the 3 ΔNGFR+ selected samples still positive
for myeloma specific rearrangements, we observed a fur-
ther decrease of myeloma contamination in samples
MM15 and MM16 (range of purging: 0–5 to 1 log). Com-
paring the frequencies of tumor load in the different
pooled data, we found a strong statistical significance
between fresh CD34+ cells vs. CD34+ cells after culture,
and after ΔNGFR selection (Table 3). When we compared
the purging results of the culture with the ΔNGFR+ cell
fraction, we failed to find a relevant statistical significance
(p > 0.1). This result suggests that the culture itself plays a
major role in the purging.Journal of Translational Medicine 2007, 5:35 http://www.translational-medicine.com/content/5/1/35
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Multiple myeloma cells: transduction and division pattern
To assess the transduction rate of myeloma cells, we
infected BM CD34+ cells of a MM patient, after adding
back to the cell population CD138+ myeloma plasma cells
sorted from the same patient (ratio 1:1). By this way we
reproduced our experimental condition setting, which
includes a mixed population of healthy CD34+ cells and
myeloma cells. In addition, in a parallel experiment, we
transduced CD138+ sorted cells at 1 × 106/well, to assess
the transduction rate on a consistent number of cells, and
at 1 cell/well, to study the division rate of tumor cells dur-
ing transduction and therefore the possibility of the single
cell to be infected by retroviral vectors (Figure 2).
Clonal transduction was performed at the same concen-
tration of cytokines and virus as in the standard cell trans-
duction, and the division pattern scored during the
culture by light microscope (n = 89 single-cell wells). At
the end of procedure we stained each well with Trypan-
blue dye, to assess the viability of the cells. Whereas trans-
duction rate of CD34+ cells was 21.4% in the mixed cell
population, no CD138+ cell was transduced, neither in
this cell population, nor in the CD138+ selected cells. The
rate of CD138+ clonal cell division during viral exposition
was 3.7%, but all cells died before the end of procedure,
as assessed by Trypan blue labelling.
Previous studies report that LTMC can sustain myeloma
cells [20]. To exclude the presence of myeloma "long-liv-
ing" contaminants, or possible myeloma precursors in the
transduced and selected cell fraction, we seeded CD34+/
ΔLNGFR+ cells of patient MM18 in a LTMC assay, adding
IL6 to the culture to favour the maintenance of the plasma
cells in culture. After 3 weeks, the cells were placed in a
CFU-C assay, picked at the end of the culture, and ana-
lyzed for specific myeloma rearrangements. 100% of the
colonies (42 out of 42) tested resulted negative for the
patient-specific rearrangement (data not shown).
Discussion
Available clinical evidences suggest that CD34+ selection
reduces myeloma contamination in PBSC (Peripheral
Blood Stem Cell) collections [5,6,24,25], however, it does
not eliminate it, and it does not improve disease-free or
overall survival of transplanted patients [8,9,26]. We
sought to improve the molecular purging of leuka-
phereses for autografting by exploiting the in-vitro biolog-
ical behaviour of myeloma cancer cells. The results
achieved with our protocol strongly suggest that opti-
mised short-culture conditions provide a major contribu-
tion to purging: rearrangement-undetectable CD34+ cells
were generated in 57% (4 out of 7) samples. To further
improve the purging results, we exposed CD34-selected
cells to a retroviral transduction with a selectable mem-
brane-associated marker. This innovative combined pro-
cedure exploits the gene transfer technique to enrich for
high repopulating-capacity CD34+ cells, and, at the same
time, to eliminate myeloma contaminants. Moreover, an
Table 1: Results of CD34+ cell selection, culture and transduction
Patient Number of CD34+ 
selected cells (× 103)
Purity of CD34+ 
selected cells (%)
Transduction (%) Number of 
ΔLNGFR selected 
cells (× 103)
Purity of 
ΔLNGFR 
selected cells (%)
%CD34+ cells 
among ΔLNGFR 
selected cells
CD34+ 
transduced cells 
vs initial CD34+ 
cells (ratio)
MM 1 1082.0 78.6 29.8 156.2 92.8 72.4 13.3
MM 2 1913.0 33.6 20.9 36.0 85.5 43.6 24.4
MM 3 887.0 87.3 32.4 456.0 93.2 60.2 35.4
MM 4 1239.0 91.2 26.7 394.6 96.9 45.1 15.8
MM 5 1229.0 95.8 20.1 238.6 85.4 62.4 12.7
MM 6 1576.0 80.6 32.1 1520.0 94.5 62.2 74.4
MM 7 4285.0 37.1 31.4 729.0 90.4 67.6 31.0
MM 8 341.0 96.8 8.5 96.4 91.7 79.7 23.3
MM 9 1000.0 86.1 38.5 490.0 89.3 68.5 39.0
MM 10* 1000.0 97.2 56.1 266.0 89.3 78.2 21.4
MM 11 500.0 77.6 33.7 78.0 77.9 75.0 15.1
MM 12 15000.0 97.2 17.0 3900.0 88.0 76.3 20.4
MM 13 1000.0 50.4 26.0 175.0 95.0 71.0 24.7
MM 14* 22300.0 98.0 56.2 7990.0 97.8 67.5 24.1
MM 15 4400.0 76.0 18.0 576.0 93.3 79.0 13.8
MM 16 2890.0 79.0 20.0 396.0 97.3 84.0 14.6
MM 17 900.0 95.0 28.5 148.0 97.4 66.0 11.4
MM 18 1740.0 78.4 26.0 234.0 95.4 38.4 6.6
MM 19 2890.0 78.0 30.0 560.0 99.8 67.9 16.9
MM 20 2100.0 98.7 26.5 170.0 98.8 89.8 7.4
Mean ± 
SD
80.6 ± 19% 28.9 ± 12% 92.5 ± 5% 67.7 ± 13% 22.3 ± 15%
CD34+ enriched cells of 19 patients were transduced with the ΔLNGFR retroviral vector, selected for transgene after 48 hours, and analyzed by flow cytometry. The last 
column shows the ratio between the number of CD34+ cells in the ΔNGFR+ selected cell population, and the initial number of CD34+ cells. * cells derived from the same 
patient.Journal of Translational Medicine 2007, 5:35 http://www.translational-medicine.com/content/5/1/35
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advantage of this approach is that it foresees the outcome
of a possible future gene therapy addressed to the CD34+
cells and their progeny.
The transduction and selection results indicate that the
procedure is clinically feasible, with a mean amount of
22.3 ± 15% final transduced and selected CD34+ cells,
with respect to the initial CD34+ cell number. We have
previously demonstrated that ΔLNGFR+ selected CD34+
cells are capable of developing a multilineage reconstitu-
tion profile in a relevant animal model [18]. Previous
reports have already assessed ex-vivo culture for purging of
tumor cells in myeloma and lymphoma [27,28], but the
long culture period (7–21 days) render these cells unsuit-
able for reinfusion.
We could not correlate our purging efficiency with cell
expansion, neither with transduction efficiency, nor with
cell recovery. The only parameter we could link with a
poor purging outcome was the ΔNGFR purity of selection.
Although it occurred in a single sample, a ΔNGFR purity
of <93% correlated with the persistency of tumor contam-
ination after culture and selection of transduced cells (see
Table 1 and 2).
MPB CD34+ cells of myeloma patients before and after culture, and transduction Figure 1
MPB CD34+ cells of myeloma patients before and after culture, and transduction. (A) Phenotypic analyses of 
CD34+ cells before and after cytokine culture, ΔNGFR transduction, and selection of transduced cells. (B) Relative fold expan-
sion in culture, and recovery after transduction and selection of total cells (open bars) and CD34+ cells (black bars), were 
measured, in comparison with the initial cell population (fresh cells).Journal of Translational Medicine 2007, 5:35 http://www.translational-medicine.com/content/5/1/35
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ΔNGFR+ selection appeared to improve the tumor load
removal, with respect to the simple culture-based purging.
However, we did not observe a complete elimination of
residual myeloma contaminants. DNA deriving from
dead cells, still present at the end of the procedure, or
actual tumor contaminants could explain the incomplete
purging. Our experiments show a very low probability for
plasma cells to be transduced in these culture conditions.
Rather, the involvement of myeloma plasma cells in
ΔLNGFR selection could occur because of their inherent
characteristics, leading them to adhere via surface Ig to
beads-coated antibodies. Since we did not reach a com-
plete purging in ΔLNGFR+ selected cells, we performed a
clonogenic analysis on a ΔLNGFR+ contaminated cell frac-
tion which suggested that the myeloma contaminants
present in the final cell fraction do not retain clonogenic
capacity.
We previously demonstrated the multilineage reconstitu-
tion potential of MPB CD34+ cells treated with the same
culture and transduction protocol in SCID-hu animal
models [18]. This particular animal model allows the dif-
ferentiation of lymphocytes in a suitable microenviron-
ment. We showed a maintained lymphoid reconstitution
potential, with differentiation of mature B and T cells after
CD34+ cell transplant. We assume that a good and early
lymphoid cell reconstitution is necessary in myeloma
patients undergoing autologous transplants to protect
against post-transplant infections [13], and probably
against early tumor relapse. Nevertheless, we acknowl-
edge the need for a more stringent assay of myeloid repop-
ulating capacity, in order to move the technique into
clinical application.
Table 3: Statistical comparison of tumor load between different cell populations
ESTIMATED DECREASE (RATIO) 95% CONFIDENCE INTERVAL P VALUE
CD34+ fresh cells versus CD34+ cells after culture 6.86 1.75 27.17 5.78 × 10-3
CD34+ fresh cells versus ΔNGFR+ selected cells 16.98 5.54 52.04 8.29 × 10-7
CD34+ after culture versus ΔNGFR+ selected cells 2.46 0.43 14.15 3.12 × 10-1
The amount of purging was evaluated in different coupled cell populations, and expressed as ratio of contaminant tumor cells (number of tumor 
cells pre purging/number of tumor cells after purging).
Table 2: Results of tumor cell purging in mobilized blood cells before and after serial purging steps
Tumor cell frequency
Log decrease
Exp. Mobilized blood aphereses CD34+ selected fresh cells CD34+ cells after culture NGFR+ selected cells
MM 3 < 1:49334 < 1:49334 N.D. < 1:49334
00- 0
MM 6# 1:2449 1:11791 < 1:89606 < 1:89606
0 0.68 > 1.56 > 1.56
MM 10 > 1:6211 > 1:28818 N.D. 1:28852
0<  0 . 6 7 - 0 . 6 7
MM 12# 1:4239 < 1:89606 < 1:89606 < 1:89606
0 > 1.32 > 1.32 > 1.32
MM 13# 1:10646 < 1:89606 < 1:89606 < 1:89606
0 > 0.92 > 0.92 > 0.92
MM 14# 1:490 1:11162 < 1:109697 < 1:109697
0 1.36 > 2.35 > 2.35
MM 15# N.D. 1:12789 1:2669 1:26667
N.D. 00 1
MM 16 N.D. > 1:12422 1:28852 1:89256
N.D. 00 . 3 7 0 . 8 6
MM 18# N.D. 1:238 < 1:44823 < 1:44823
N.D. 0 > 2.27 > 2.27
MM 19 N.D. 1:89286 < 1:89606 < 1:89606
N.D. 0>  0 >  0
POOLED DATA 1:5291 1:12270 1:84602 1:208333
0 0.36 1.2 1.59
Mobilized blood cells were analyzed after different purging steps for tumor load, where the specific MM marker was available. DNA from 1 × 104, or 2 × 104 cells was 
amplified to detect MM contaminants. For 6 patients (#) serial dilutions of DNA were performed, with 0.5 logs step dilutions. The quantification of malignant cells in each cell 
fraction was calculated according to the single-hit Poisson model, and expressed as tumor cell frequency (1:x). The logarithmic decrease (lower part of cells) was calculated 
with respect to the foregoing unpurged sample indicated with "0". When the frequency of tumor contamination was below the detection threshold of the system, PCR were 
scored as negative (clear-shaded cells). The pooled data represent frequency determinations, according to the statistical method by Taswell.
N.D. = not doneJournal of Translational Medicine 2007, 5:35 http://www.translational-medicine.com/content/5/1/35
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Recently, several clinical leukemia events reported by
Hacein-Bey-Abina et al. in severe combined immunodefi-
ciency-X linked (SCID-X) patients treated with γ-chain
transduced CD34+ cells [29] raised questions about the
general safety of retrovirus-based gene therapy. The issue
is still under intensive investigation with extensive analy-
ses performed on transduced cells [30]. So far, no other
group has reported similar adverse events, despite a high
number of clinical trials performed in more than 10 years
of gene therapy and gene marking studies [31]. Still, a jus-
tified caution in evaluating risks and benefits of a gene
therapy clinical procedure is now mandatory.
Among the performed sequential purging steps, the CD34
selection was the least efficient: we could also consider
applying the culture protocol directly to the whole leuka-
pheresis. Provided that we reach experimental evidences
of a similar purging, this setting would simplify the cell
manipulation process and render the procedure more
suitable for a clinical application.
Conclusion
We conclude that the culture purging approach we have
devised could be a feasible and efficient procedure for MM
patients undergoing autologous transplantation. There is
also a tendency of myeloma contaminants to further
decrease after transduction and selection of CD34+ cells,
as compared with the simple culture. An advantage of the
transduction protocol is a potentially myeloma-free pop-
ulation of marked cells, detectable over time. Gene mark-
ing of autografted cells has been shown to be a valuable
tool to trace long-term reconstitution of the host [32], and
the origin of disease relapse [33]. A pilot study for MM
patients eligible to high dose chemotherapy and autolo-
gous transplant would clarify the effectiveness of the purg-
ing transplant approach described in this work. The safe
reconstitution capacity of CD34+ transduced cells could
also allow a future gene therapy trial directed to hemat-
opoietic CD34+ cells.
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